法国生物技术公司Aqemia利用人工智能技术加速新药的发现和设计，最近成功获得了3000万欧元的A轮融资追加资金，使得该轮总融资金额达到了6000万欧元。这家总部位于巴黎的公司由Wendel Growth领投，同时现有投资者包括法国风险投资公司Eurazeo、公共银行Bpifrance和Elaia也参与了跟投。
Aqemia开发的人工智能驱动技术，声称可以大大加速药物分子的发现和设计，这些分子未来可能被开发成为治疗各种疾病的药物。该技术有望为药物研发领域带来革命性的变革，并为病患带来更加快速和有效的治疗方案。
这家公司的融资成功，不仅显示出投资者对其人工智能药物发现技术的信心，也反映了资本市场对于生物技术领域的持续关注和热捧。Aqemia的未来发展值得期待。
英文标题：Aqemia Secures Additional €30 Million in Funding for AI-Driven Drug Discovery
英文关键词：AI drug discovery, funding, biotechnology
英文新闻内容：
French biotech company Aqemia, which uses artificial intelligence to accelerate the discovery and design of new drugs, has recently secured an additional €30 million in funding for its Series A round, bringing the total funding amount to €60 million. The company, headquartered in Paris, was led by Wendel Growth with participation from existing investors including French venture capital firm Eurazeo, public bank Bpifrance, and Elaia.
Aqemia has developed a technology driven by artificial intelligence that claims to significantly speed up the discovery and design of drug molecules, which could potentially become drugs for treating various diseases. The technology is expected to bring revolutionary changes to the field of drug development and provide patients with more rapid and effective treatment options.
The success of the company’s fundraising not only shows investor confidence in its AI-driven drug discovery technology but also reflects the ongoing interest and enthusiasm of the capital market for the biotechnology sector. Aqemia’s future development is值得期待.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 1